Sepsis: in search of cure. (Q30251753)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26995266 AND SRC:MED&resulttype=core&format=json

11 March 2020

title

Sepsis: in search of cure (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26995266 AND SRC:MED&resulttype=core&format=json

11 March 2020

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26995266 AND SRC:MED&resulttype=core&format=json

11 March 2020

author name string

Chikkamenahalli Lakshminarayana Lakshmikanth

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26995266 AND SRC:MED&resulttype=core&format=json

11 March 2020

Shancy Petsel Jacob

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26995266 AND SRC:MED&resulttype=core&format=json

11 March 2020

Vyala Hanumanthareddy Chaithra

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26995266 AND SRC:MED&resulttype=core&format=json

11 March 2020

Hugo Caire de Castro-Faria-Neto

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26995266 AND SRC:MED&resulttype=core&format=json

11 March 2020

publication date

19 March 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26995266 AND SRC:MED&resulttype=core&format=json

11 March 2020

published in

Inflammation Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26995266 AND SRC:MED&resulttype=core&format=json

11 March 2020

volume

65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26995266 AND SRC:MED&resulttype=core&format=json

11 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26995266 AND SRC:MED&resulttype=core&format=json

11 March 2020

page(s)

587-602

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26995266 AND SRC:MED&resulttype=core&format=json

Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes

11 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Pathogenesis of Multiple Organ Failure in Sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Coordinated Molecular Cross-Talk between Staphylococcus aureus, Endothelial Cells and Platelets in Bloodstream Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

How bacterial pathogens colonize their hosts and invade deeper tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

The Response of CD1d-Restricted Invariant NKT Cells to Microbial Pathogens and Their Products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Gram-positive and gram-negative bacterial toxins in sepsis: a brief review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Novel strategies for the treatment of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Trial watch: Sepsis study failure highlights need for trial design rethink

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

High levels of serum macrophage migration inhibitory factor and interleukin 10 are associated with a rapidly fatal outcome in patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

suPAR as a prognostic biomarker in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Why have clinical trials in sepsis failed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

The demise of early goal-directed therapy for severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

The disconnect between animal models of sepsis and human sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Role of circulating lymphocytes in patients with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Initial Emergency Department Diagnosis and Management of Adult Patients with Severe Sepsis and Septic Shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Dopamine mediates vagal modulation of the immune system by electroacupuncture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Epidemiology of severe sepsis in India: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Role of bacteria in oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Nosocomial bloodstream infection and clinical sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Pneumonia in the context of severe sepsis: a significant diagnostic problem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Characteristics and outcomes of culture-negative versus culture-positive severe sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Richard Friedrich Johannes Pfeiffer. 1858-1945

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Structural characterization of a model gram-negative bacterial surface using lipopolysaccharides from rough strains of Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Toll-like receptor signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Structure and function of lipopolysaccharide binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Toll-like receptors in innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

LPS/TLR4 signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Lipopolysaccharide regulates proinflammatory cytokine expression in mouse myoblasts and skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Effects of the TLR2 agonists MALP-2 and Pam3Cys in isolated mouse lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Pathogen recognition and inflammatory signaling in innate immune defenses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

A database of bacterial lipoproteins (DOLOP) with functional assignments to predicted lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

The architecture of the murein (peptidoglycan) in gram-negative bacteria: vertical scaffold or horizontal layer(s)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Chemical Characterization, Spatial Distribution and Function of a Lipoprotein (Murein-Lipoprotein) of the E. coli Cell Wall. The Specific Effect of Trypsin on the Membrane Structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Variability in in vitro macrophage activation by commercially diverse bulk echinacea plant material is predominantly due to bacterial lipoproteins and lipopolysaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Mycobacterial lipopeptides elicit CD4 CTLs in Mycobacterium tuberculosis-infected humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

The Prognostic Value of suPAR Compared to Other Inflammatory Markers in Patients with Severe Sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

After Xigris, researchers look to new targets to combat sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

A randomized trial of protocol-based care for early septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Goal-directed resuscitation for patients with early septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Trial of Early, Goal-Directed Resuscitation for Septic Shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Management of neonatal sepsis in term newborns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Cecal ligation puncture procedure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Colon ascendens stent peritonitis (CASP)--a standardized model for polymicrobial abdominal sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Cecal ligation and puncture versus colon ascendens stent peritonitis: two distinct animal models for polymicrobial sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Distance of Cecum Ligated Influences Mortality, Tumor Necrosis Factor-Alpha and Interleukin-6 Expression following Cecal Ligation and Puncture in the Rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Dependence of positive effects of granulocyte colony-stimulating factor on the antibiotic regimen: evaluation in rats with polymicrobial peritonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Impact of antibiotic treatment intensity on long-term sepsis-associated kidney injury in a polymicrobial peritoneal contamination and infection model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Mechanisms and functional consequences of liver failure substantially differ between endotoxaemia and faecal peritonitis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Beneficial effect of clopidogrel in a mouse model of polymicrobial sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Establishment of a sepsis model following implantation of Klebsiella pneumoniae-infected fibrin clot into the peritoneal cavity of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Comparison of live bacteria infusions in a porcine model of acute respiratory failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Adenosine-5'-triphosphate (ATP) protects mice against bacterial infection by activation of the NLRP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Novel Regulators of the Systemic Response to Lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Animal models of sepsis and sepsis-induced kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

The combination of a tumor necrosis factor inhibitor and antibiotic alleviates staphylococcal arthritis and sepsis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

E5531, a pure endotoxin antagonist of high potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Microbiological Diagnosis of Sepsis: Polymerase Chain Reaction System Versus Blood Cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Prospective comparison of a PCR assay and a microbiological culture technique for identification of pathogens from blood and non-blood samples in septic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Sepsis-associated disseminated intravascular coagulation and thromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Validation of a modified thromboelastometry approach to detect changes in fibrinolytic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Prognosis Biomarkers of Severe Sepsis and Septic Shock by 1H NMR Urine Metabolomics in the Intensive Care Unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

21 January 2018

Sepsis and the heart.

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Levosimendan but not norepinephrine improves microvascular oxygenation during experimental septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Levosimendan increases portal blood flow and attenuates intestinal intramucosal acidosis in experimental septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Selepressin, a new V1A receptor agonist: hemodynamic comparison to vasopressin in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Alkaline phosphatase: a possible treatment for sepsis-associated acute kidney injury in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Histone structure and nucleosome stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Release and activity of histone in diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Extracellular histones are major mediators of death in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Extracellular Histones Are Mediators of Death through TLR2 and TLR4 in Mouse Fatal Liver Injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Circulating Histone Concentrations Differentially Affect the Predominance of Left or Right Ventricular Dysfunction in Critical Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Extracellular histone H3 levels are inversely correlated with antithrombin levels and platelet counts and are associated with mortality in sepsis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

HMG proteins: dynamic players in gene regulation and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

HMG chromosomal proteins in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

HMGB1, a potent proinflammatory cytokine in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

HMG-1 as a late mediator of endotoxin lethality in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Immunomodulatory drugs regulate HMGB1 release from activated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Toll-like receptor 4 on islet β cells senses expression changes in high-mobility group box 1 and contributes to the initiation of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Sepsis-induced organ failure is mediated by different pathways in the kidney and liver: acute renal failure is dependent on MyD88 but not renal cell apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Therapeutic Effects of Treatment with Anti-TLR2 and Anti-TLR4 Monoclonal Antibodies in Polymicrobial Sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Mesenchymal stem cells: a new trend for cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Therapeutic effects of bone marrow-derived mesenchymal stem cells on pulmonary impact injury complicated with endotoxemia in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Mesenchymal stem cells as a therapeutic tool to treat sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Hydrocortisone therapy for patients with septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Drotrecogin alfa (activated) in adults with septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Multicenter, randomized, placebo-controlled phase III study of pyridoxalated hemoglobin polyoxyethylene in distributive shock (PHOENIX).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00011-016-0937-Y

Antimicrobial Peptides in Human Sepsis

21 January 2018

1 reference

12 December 2020

Appreciation of trimetazidine treatment in experimental sepsis rat model

1 reference

12 December 2020

The influence of G-CSF addition to antibiotic treatment of experimental sepsis on pulmonary tissue.

1 reference

12 December 2020

Intravenous infusion of mesenchymal stem cells is associated with improved myocardial function during endotoxemia

1 reference

12 December 2020

Acute inflammatory response to endotoxin in mice and humans

1 reference

12 December 2020

LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis

1 reference

12 December 2020

Macrophage Migration Inhibitory Factor and Host Innate Immune Defenses against Bacterial Sepsis

1 reference

12 December 2020

Treatment of Gram-Negative Septic Shock with Human IgG Antibody to Escherichia coli J5: A Prospective, Double-Blind, Randomized Trial

1 reference

12 December 2020

Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure

1 reference

12 December 2020

Monitoring of organ dysfunction in sepsis/systemic inflammatory response syndrome: novel strategies

1 reference

12 December 2020

Infection detection: Identifying & understanding sepsis in the prehospital setting, part 1 of 2.

1 reference

12 December 2020

HMGB1 acts in synergy with lipopolysaccharide in activating rheumatoid synovial fibroblasts via p38 MAPK and NF-κB signaling pathways.

1 reference

12 December 2020

Sexual dimorphism of the chromatographic profiles of I-compounds (endogenous deoxyribonucleic acid modifications) in rat liver

1 reference

12 December 2020

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

1 reference

12 December 2020

E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators

1 reference

12 December 2020

Protein tyrosine kinase activation is required for lipopolysaccharide induction of cytokines in human blood monocytes.

1 reference

12 December 2020

Borrelia burgdorferi outer surface lipoproteins OspA and OspB possess B-cell mitogenic and cytokine-stimulatory properties

1 reference

12 December 2020

The abdomen as source of sepsis in critically ill patients.

1 reference

12 December 2020

Troponin I serum levels predict the need of dialysis in incident sepsis patients with acute kidney injury in the intensive care unit

1 reference

12 December 2020

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 reference

12 December 2020

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group

1 reference

12 December 2020

High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function.

1 reference

12 December 2020

Characteristics of clinical sepsis reflected in a reliable and reproducible rodent sepsis model

1 reference

12 December 2020

Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.

1 reference

12 December 2020

Effects of lipopolysaccharide on the expression of proinflammatory cytokines and chemokines and the subsequent recruitment of immunocompetent cells in the oviduct of laying and molting hens

1 reference

12 December 2020

Niacin and Selenium Attenuate Sepsis-Induced Lung Injury by Up-Regulating Nuclear Factor Erythroid 2-Related Factor 2 Signaling.

1 reference

12 December 2020

HMG-1 as a mediator of acute lung inflammation

1 reference

12 December 2020

1 reference

12 December 2020

Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis

1 reference

12 December 2020

Modeling sepsis in the laboratory: merging sound science with animal well-being

1 reference

12 December 2020

Analysis of IL-1 β release from cryopreserved pooled lymphocytes in response to lipopolysaccharide and lipoteichoic acid

1 reference

12 December 2020

Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group

1 reference

12 December 2020

Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture

1 reference

12 December 2020

Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism

1 reference

12 December 2020

p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group

1 reference

12 December 2020

Escherichia coli Braun lipoprotein induces a lipopolysaccharide-like endotoxic response from primary human endothelial cells

1 reference

12 December 2020

Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice

1 reference

12 December 2020

Increases in serum macrophage migration inhibitory factor in patients with severe sepsis predict early mortality

1 reference

12 December 2020

Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group

1 reference

12 December 2020

Factors influencing wound infection (a prospective study of 280 cases)

1 reference

12 December 2020

The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study

1 reference

12 December 2020

Role of Toll-like receptors in HMGB1 release from macrophages

1 reference

12 December 2020

Editorial: Mouse models to study sepsis syndrome in humans

1 reference

12 December 2020

Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses

1 reference

12 December 2020

Trimetazidine prevents macrophage-mediated septic myocardial dysfunction via activation of the histone deacetylase sirtuin 1

1 reference

12 December 2020

Lysosome and Cytoskeleton Pathways Are Robustly Enriched in the Blood of Septic Patients: A Meta-Analysis of Transcriptomic Data

1 reference

12 December 2020

Sepsis Associated Encephalopathy.

1 reference

12 December 2020

Beneficial actions of CP-0127, a novel bradykinin receptor antagonist, in murine traumatic shock

1 reference

12 December 2020

Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group

1 reference

12 December 2020

Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group

1 reference

12 December 2020

The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin

1 reference

12 December 2020

Expression of HMGB1 in septic serum induces vascular endothelial hyperpermeability

1 reference

12 December 2020

Bacterial endotoxin: molecular relationships of structure to activity and function

1 reference

12 December 2020